This study compared ex vivo relaxing responses to the naturally occurring human hormone estetrol (E 4 ) vs 17b-estradiol (E 2 ) in eight different vascular beds. Arteries were mounted in a myograph, contracted with either phenylephrine or serotonin, and cumulative concentrationresponse curves (CRCs) to E 4 and E 2 (0 . 1-100 mmol/l) were constructed. In all arteries tested, E 4 had lower potency than E 2 , although the differential effect was less in larger than smaller arteries. In uterine arteries, the nonselective estrogen receptor (ER) blocker ICI 182 780 (1 mmol/l) caused a significant rightward shift in the CRC to both E 4 and E 2 , indicating that the relaxation responses were ER dependent. Pharmacological blockade of nitric oxide (NO) synthases by N u -nitro-L-arginine methyl ester (L-NAME) blunted E 2 -mediated but not E 4 -mediated relaxing responses, while inhibition of prostaglandins and endothelium-dependent hyperpolarization did not alter relaxation to either E 4 or E 2 in uterine arteries. Combined blockade of NO release and action with L-NAME and the soluble guanylate cyclase (sGC) inhibitor ODQ resulted in greater inhibition of the relaxation response to E 4 compared with E 2 in uterine arteries. Endothelium denudation inhibited responses to both E 4 and E 2 , while E 4 and E 2 concentration-dependently blocked smooth muscle cell Ca 2C entry in K C -depolarized and Ca 2C -depleted uterine arteries. In conclusion, E 4 relaxes precontracted rat arteries in an artery-specific fashion. In uterine arteries, E 4 -induced relaxations are partially mediated via an endothelium-dependent mechanism involving ERs, sGC, and inhibition of smooth muscle cell Ca 2C entry, but not NO synthases or endothelium-dependent hyperpolarization.
Introduction
The hormone estetrol (estra-1,3,5(10)-trien-3,15a-16a,17b-tetrol or E 4 ) was discovered in 1965 (Hagen et al. 1965 ). E 4 is produced in nature from 17b-estradiol (E 2 ) and estrol (E 3 ) only by the human fetal liver during pregnancy via 15a-and 16a-hydroxylase (Schwers et al. 1965 , Gurpide et al. 1966 . The concentration of E 4 increases during pregnancy in both the fetus and the mother, but 24 h after delivery, the level is undetectable.
The chemical structure of E 4 is closely related to that of E 2 , but the pharmacokinetic, metabolic, and endocrinological profile of E 4 is substantially different from that of E 2 . E 2 has high affinity for the estrogen receptor a (ERa) and ERb (K i values: 0 . 2 and 0 . 05 nmol/l respectively), while E 4 has low-to-moderate affinity for ERa and ERb (K i values: 4 . 9 and 19 nmol/l respectively; Coelingh Bennink et al. 2008a ). E 2 has very low oral availability because over 99% of an oral dose is converted into estrone (E 1 ) and E 1 sulfate. Most of the circulating E 2 is bound to either albumin or sex hormone binding globulin (SHBG), further decreasing plasma levels of free E 2 by a factor of about 30. By contrast, E 4 does not undergo phase I metabolism by human HepG2 cells and does not bind to SHBG (Hammond et al. 2008) . As a result of these favorable metabolic and protein binding properties, E 4 has excellent oral potency despite its low-to-moderate affinity for ERs. E 4 has been studied in many validated models and has been shown to behave as a full ER agonist, similar to E 2 , in most of these (Coelingh Bennink et al. 2008b , Heegaard et al. 2008 , Visser & Coelingh Bennink 2009 ). However, important differences between E 4 and E 2 were noted. E 4 did not induce synthesis of SHBG in vitro as did E 2 (Hammond et al. 2008) . Recent studies showed that E 4 behaved as an ER antagonist in in vitro and in vivo models of estrogen-dependent breast tumors in the presence of E 2 . E 2 behaved as full agonist in these models (Coelingh Bennink et al. 2008c ). E 4 is now undergoing clinical testing as the estrogenic component of a combined oral contraceptive and for its effects on breast tumors.
The physiological function of E 4 is not completely understood, although a role in regulating uterine blood flow has been suggested. Unilateral intrauterine injection of E 4 in nonpregnant oophorectomized ewes has been shown to increase uterine blood flow, although with a 15-to 30-fold lower potency than E 3 (Levine et al. 1984) . Similarly, administration of E 2 to ovariectomized ewes results in a rapid uterine vasodilation leading to a rise in uterine blood flow within 30-45 min (Killam et al. 1973 ). This rise in uterine blood flow is partially mediated via the release of nitric oxide (NO) and resultant increases in cGMP secretion, as shown by local infusion of the NO synthase blocker N u -nitro-L-arginine methyl ester (L-NAME; Van Buren et al. 1992 , Rosenfeld et al. 1996 . The dilating effect of E 2 on ovine uterine arteries is ER dependent, as shown by local infusion of the nonselective ER blocker ICI 182 780 in nonpregnant ewes (Magness et al. 2005) .
To further profile E 4 , this study was designed to study the in vitro vasorelaxing effects of E 4 and to compare them with those of E 2 . The objectives of this study were 1) to determine the ex vivo relaxing effects of E 4 compared to E 2 in rat uterine, thoracic aortic, carotid, mesenteric, pulmonary, renal, middle cerebral, and septal coronary arterial segments; 2) to assess the involvement of ERs in the vasorelaxing response to E 4 in uterine arteries; and 3) to assess the endothelium-dependent and endothelium-independent vasorelaxing effects of E 4 in uterine arteries. The uterine artery was chosen for assessment of the acute vasoactive properties of E 4 and for comparison of these to the effects of E 2 because the uterine arterial circulation is known to be highly sensitive to the vasodilator effects of E 2 . The uterine arteries are exposed to high physiological levels of E 2 during the follicular and luteal phases of the menstrual cycle and during pregnancy, resulting in major increases in uterine blood flow (Magness 1998 ).
Materials and Methods

Animals
A total of 40 female nulliparous Sprague Dawley rats (age 12 weeks) were obtained from Charles River Breeding Laboratories, maintained at constant humidity (60G5%), temperature (24G1 8C), and light cycle (0600-1800 h), and fed a standard rat pellet diet (2016 Teklad Global 16% Protein Rodent Diet (Harlan Laboratories, Teklad Diets, Madison, WI, USA) ad libitum. All protocols were approved by the Institutional Animal Care and Use Committee at the University of Alabama at Birmingham and were consistent with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.
Vessel preparation
Rats were killed by CO 2 inhalation and the uterus, thoracic aorta, left common carotid artery, mesentery, lungs, left kidney, brains, and heart were removed and placed in cold KrebsRinger buffer (KRB) with the following composition (in mM): 118 . 5 NaCl, 4 . 7 KCl, 2 . 5 CaCl 2 , 1 . 2 MgSO 4 , 1 . 2 KH 2 PO 4 , 25 . 0 NaHCO 3 , and 5 . 5 glucose (all purchased from Sigma-Aldrich). Tissue samples were pinned down onto a 90 mm glass petri dish coated with black Sylgard and soaked in cold KRB. Main uterine arterial segments running along both uterine horns were cleared of adipose and connective tissues. The thoracic aorta and left common carotid artery were cleaned of connective tissue and cut into 2 . 5-3 mm segments.
A fourth-order branch segment of the superior mesenteric artery was dissected from the mesentery; a small (200-300 mm in diameter) pulmonary arterial segment was dissected from the lung; a segment of the left main renal artery was dissected, and a segment of the middle cerebral artery was dissected from the brain. The atria and the left ventricle were removed to expose the interventricular septum of the heart, and a segment of the septal coronary artery was dissected. Aortic and carotid artery segments were mounted between two stainless steel pins, whereas the other segments (all 2 mm long) were mounted between two stainless steel jaws connected with two wires (40 mm in diameter) through the lumen of the segment in a myograph chamber (Danish Myo Technology, Inc., Aarhus, Denmark) filled with 5 ml KRB solution, maintained at 37 8C, and continuously aerated with 95% O 2 and 5% CO 2 . Four arterial segments were analyzed in parallel. The remaining segments were temporarily stored at 4 8C.
Determination of optimal diameters
Thoracic aortae and carotid and pulmonary arteries were passively stretched according to a procedure first described by Mulvany & Halpern (1977) . Briefly, the segments were distended stepwise in 100 mm increments measured with a built-in micrometer and the wall tension (N/m) was recorded using data acquisition (Powerlab 8/35, ADInstruments, Colorado Springs, CO, USA) and recording Software (ChartLab7, Colorado Springs, CO, USA). Thoracic aortic segments and carotid arteries were stretched at wall tension corresponding to a pressure of 90 mmHg, whereas pulmonary arteries were stretched at a wall tension corresponding to 40 mmHg. At this passive wall tension, segments were contracted with high K C KRB (60 mmol/l KCl in KRB solution; replacing equimolar NaCl with KCl), thus generating active wall tension, which was set to a 100% contraction level.
All other arterial segments were progressively and actively stretched to the internal diameter at which the largest contractile response to 10 mmol/l norepinephrine (NE) or 60 mmol/l K C KRB (middle cerebral arteries) was obtained. This internal diameter was referred to as the optimal diameter and the corresponding active wall tension was set to a 100% contraction level.
Arterial integrity was assessed by contracting arterial segments to either 1 mmol/l phenylephrine (PHE; for uterine, thoracic aorta, carotid, mesenteric, pulmonary, and renal arteries) or 0 . 1-1 mmol/l serotonin (5-HT; for middle cerebral and septal coronary arteries), followed by endothelium-dependent relaxation with 1 mmol/l acetylcholine (ACh). Arteries that relaxed immediately (O50% of relaxation) were considered to have a functional endothelium.
Experimental protocols
Cumulative concentration-response curves (CRCs) were constructed with PHE (0 . 16-20 mmol/l) or 5-HT (0 . 001-10 mmol/l). Arterial segments were then washed with KRB and after 10 min were contracted with a single concentration of the appropriate contractile agent, resulting in a near maximal contraction (80-100% of active wall tension obtained with 10 mmol/l NE or 60 mmol/l K C depolarization). During a stable contraction, a CRC to E 4 (0 . 1-100 mmol/l) was performed. After a 30-min washout period, segments were again contracted with the appropriate contractile agent and the CRC was repeated with E 2 (0 . 1-100 mmol/l). The order of application of the estrogenic compounds was altered on every experimental day. In a subset of uterine arteries, CRCs to E 4 and E 2 were run in parallel. Relaxing responses to E 2 and E 4 were unaltered when run in series compared with parallel application.
We uterine arterial relaxing responses to E 4 and E 2 . To study the involvement of ERs (ERa and ERb) in the uterine arterial relaxing responses to E 4 in comparison to E 2 , arteries were incubated for 30 min with the nonselective ER antagonist ICI 182 780 (7a, 4, 5, 5, sulfinyl]nonyl] estra-1,3,5(10)-triene-3,17-diol; 1 mmol/l; Wakeling et al. 1991) , after which the arterial segments were contracted with a single concentration of PHE (1-10 mmol/l) followed by a CRC to either E 4 or E 2 .
To assess whether E 4 triggered the release of vasodilator and/or contractile prostaglandins in uterine arteries, the cyclooxygenase inhibitor indomethacin (INDO; 10 mmol/l) was used. The involvement of endothelium-derived NO in uterine arterial relaxing responses to E 4 was assessed using the nonselective NO synthase blocker L-NAME (100 mmol/l). The combined application of L-NAME and INDO was used to assess the role of endothelium-derived hyperpolarizing factor (EDHF) in E 4 -mediated relaxing responses in uterine arteries. The involvement of cGMP in E 4 -mediated relaxation was assessed by incubating uterine arteries with L-NAME, INDO, and the soluble guanylate cyclase (sGC) inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 10 mmol/l).
The hyperpolarization response, involving both release of EDHF and spread of a hyperpolarizing current, is initiated in the endothelium via activation of small and intermediate calcium-activated K C channels (SK Ca and IK Ca respectively; Burnham et al. 2002) . Blockade of both K Ca channels results in complete blockade of the EDHF response in rat mesenteric arteries (Crane et al. 2003) . However, in some arteries, such as skeletal arterioles and coronary arteries, the large-conductance K Ca (BK Ca ) is involved in EDHF-mediated responses (Feher et al. 2010 ). We did not attempt to study the role of the BK Ca channel blocker iberiotoxin in E 4 -and E 2 -mediated relaxing responses in uterine arteries. 6, 12, 19, 20, 25, 27:13, 18:21, ,5,12,16] tetraazacyclotricosine-5,13-diium dibromide (UCL 1684; 1 mmol/l; Campos Rosa et al. 2000) was used to block SK Ca channels and 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34; 1 mmol/l; Wulff et al. 2000) was used to block IK Ca channels. All inhibitors were applied 30 min before the addition of PHE. After washing with KRB, arterial segments were again incubated with the appropriate pharmacological blocker(s) and subsequently (after 10 min) contracted with PHE (1-10 mmol/l) followed by a CRC to either E 4 or E 2 .
The role of endothelium in E 4 -mediated relaxing responses was assessed using endothelium-denuded uterine arteries. The endothelium was mechanically removed by gently rubbing the lumen with a human hair (Osol et al. 1989) . Successful denudation was achieved when relaxation to 1 mmol/l ACh was absent. Endothelium-independent relaxing responses to the NO donor sodium nitroprusside (SNP; 0 . 1-10 000 nmol/l) were performed in PHE (10 mmol/l)-contracted endothelium-intact arteries.
The potential inhibitory effect of E 4 on voltage-operated smooth muscle cell Ca 2C entry was assessed by incubating endothelium-intact uterine arteries with three different concentrations (10, 30, and 100 mmol/l) of E 4 or vehicle (ethanol) for 10 min in Ca 2C -free and high K C KRB solution, followed by a cumulative addition of CaCl 2 (0 . 01-2 . 5 mmol/l). To rule out modulating effects of other endothelium-derived relaxing factors, arteries were incubated with L-NAME (100 mmol/l), INDO (10 mmol/l), and ODQ (10 mmol/l). Results were compared with three different concentrations (3, 10, and 30 mmol/l) of E 2 .
Drugs E 4 was provided by Pantarhei Bioscience B.V. (Zeist, The Netherlands) and dissolved in ethanol (stock solution of 10 mmol/l). ACh, endothelin-1, L-NAME, NE, PHE, serotonin, and SNP were purchased from Sigma-Aldrich and dissolved in distilled H 2 O. INDO and E 2 (Sigma-Aldrich) were dissolved in ethanol (stock solutions of 10 mmol/l). TRAM-34 (Sigma), ODQ (EMD Chemicals, Gibbstown, NJ, USA), PPT, DPN, and UCL 1684 (all from Tocris Bioscience, Ellisville, MO, USA) were dissolved in DMSO.
Data and statistical analysis
Contractile responses were expressed as a percentage of the maximal contractile response to 10 mmol/l NE or 60 mmol/l K C before the administration of any pharmacological inhibitor. Relaxing responses were expressed as a percentage of the maximal contractile response to PHE or 5-HT. Individual CRCs were fitted to a sigmoid regression curve (GraphPad Prism 5.0). As the sigmoidal curve of E 4 could not be fully defined, a constant plateau value (set to 100%) was defined in order for GraphPad Prism to calculate a LOGEC 50 (pEC 50 value indicating sensitivity). Maximal relaxation to the highest concentration of E 4 or E 2 (E max ) and pEC 50 values are shown as meanGS.E.M. Statistical significance of effects and differences were analyzed using either one-way ANOVA (comparison of pEC 50 and E max ) or twoway ANOVA (comparison of CRCs). A Bonferroni post hoc test was used to compare multiple groups. A P value !0 . 05 was considered statistically significant.
Results
Arterial integrity
Optimal diameters of uterine arteries measured in the wire myograph averaged 317G3 mm and arteries developed an average active wall tension of 4 . 81G0 . 10 N/m in response to 10 mmol/l NE. Optimal diameters and active wall tensions for all artery types are summarized in Table 1 . Sensitivity (pEC 50 ) and maximal contraction to PHE (uterine, carotid, mesenteric, pulmonary, and renal artery) or 5-HT (middle cerebral and septal coronary artery) and sensitivity and maximal relaxations to 1 mmol/l ACh and the NO donor SNP for all arteries are shown in Table 2 .
Vasorelaxing responses to E 4
In uterine arteries, pEC 50 for the control estrogenic compound E 2 averaged 5 . 44G0 . 05 and reached a near maximal relaxation (E max : 93G1%) in response to the highest concentration tested (100 mmol/l; Tables 3 and 4 and Fig. 1A ). pEC 50 and E max for E 4 were significantly lower (4 . 36G0 . 07 and 74G4% respectively; Tables 3 and 4 and Fig. 1A) . Hence, in uterine arteries, E 4 was a 14-fold less potent vasodilator compared with E 2 . Vasorelaxing properties of E 4 compared with E 2 for the other seven arterial types are shown in Fig. 1B through H and are summarized in Tables 3  and 4 . E 4 resulted in much lower variability than E 2 in pEC 50 and E max values for all artery types tested (Tables 3 and 4) . Larger arteries (aorta, carotid, and renal) had lower pEC 50 and E max than smaller arteries (mesenteric, pulmonary, middle cerebral, septal coronary, and uterine). 
NE, norepinephrine. n denotes the total number of rats used. Fig. 2A ).
The nonselective ER blocker ICI 182 780 (1 mmol/l) resulted in significant rightward shifts in the CRCs to E 4 and E 2 in uterine (Fig. 2B) (Fig. 2B) . For E 2 , pEC 50 averaged 5 . 56G0 . 07 in vehicle and 5 . 12G0 . 05 in ICI 182 780-treated uterine arteries (Fig. 2B) .
Role of endothelium-derived relaxing factors in uterine arterial relaxing responses to E 4
The cyclooxygenase inhibitor INDO (10 mmol/l) did not significantly alter sensitivity to E 4 or E 2 (Fig. 3A) . The NO synthase blocker L-NAME (100 mmol/l) caused a significant rightward shift in the CRC to E 2 , but not to E 4 (Fig. 3B) .
The same trend as with L-NAME alone was observed when uterine arteries were incubated with both L-NAME and INDO (Fig. 3C) . We next tested the role of cGMP in mediating the response to E 4 and E 2 by preventing NO release and action by blocking the sGC with ODQ (10 mmol/l) in combination with L-NAME and INDO. Interestingly, blockade of cGMP release blunted the response to E 4 but not to E 2 (Fig. 3D) . The role of EDHF in mediating relaxing responses was pharmacologically tested by the addition of TRAM-34 (1 mmol/l) and UCL 1684 (1 mmol/l), inhibitors of SK Ca and IK Ca respectively. Inhibition of SK Ca and IK Ca channels in the combined presence of L-NAME and INDO did not alter the response to E 4 or E 2 (Fig. 3E) .
The contribution of the endothelium to relaxing responses to E 4 was assessed by mechanical removal of the endothelium. Successful denudation was confirmed by the absence of relaxation to 1 mM ACh in PHE-contracted arteries (0G1%). A significant rightward shift in the CRCs to E 4 and E 2 was observed in endothelium-denuded compared with endothelium-intact uterine arteries (Fig. 3F) . Table 5 summarizes the effects of pharmacological inhibitors and endothelial denudation on the vasodilator properties of E 4 compared with E 2 in rat uterine arteries. Table 3 Vasorelaxing properties (sensitivity and maximal relaxing responses) of E 2 compared with E 4 in isolated and endothelium-intact rat uterine, aorta, carotid, and mesenteric (fourth-order) arteries. Arteries were contracted with the appropriate contractile agent before application of the estrogenic compound. The contraction before application of E 4 or E 2 is expressed as percentage of the contraction in response to 10 mmol/l NE. The sensitivity (pEC 50 ) of E 4 or E 2 is calculated with GraphPad Prism Software as described in the Materials and Methods section and denotes the negative logarithmic concentration of E 4 or E 2 that induces 50% relaxation compared with the maximal relaxation (E max Table 4 Vasorelaxing properties (sensitivity and maximal relaxing responses) of E 2 compared to E 4 in isolated and endothelium-intact rat pulmonary, renal, middle cerebral, and septal coronary arteries. Arteries were contracted with the appropriate contractile agent before application of the estrogenic compound. The contraction before application of E 4 or E 2 is expressed as percentage of the contraction in response to 10 mmol/l NE. The sensitivity (pEC 50 ) of E 4 or E 2 is calculated with GraphPad Prism Software as described in the Materials and Methods section and denotes the negative logarithmic concentration of E 4 or E 2 that induces 50% relaxation compared to the maximal relaxation (E max Inhibition of calcium entry by E 4 in K C -depolarized uterine arteries From Fig. 3F , it is clear that there is a significant endotheliumindependent relaxation response to both E 4 and E 2 . We therefore analyzed whether E 4 could inhibit the entry of (Fig. 4A ) and 3 mmol/l E 2 (Fig. 4B) . Next, we compared the inhibitory effects of higher concentrations of E 4 (30 and 100 mmol/l) and E 2 (10 and 30 mmol/l). A concentration-dependent inhibitory effect of both E 4 and E 2 was observed. Overall, the results in Fig. 4 show that E 4 has tenfold lower potency than E 2 in inhibiting Ca 2C entry in depolarized smooth muscle cells.
Discussion
This study assessed the ex vivo relaxing potency of the steroid hormone E 4 in comparison to E 2 in eight arterial beds, i.e. uterine artery, thoracic aorta, the left common carotid artery, the fourth-order branch of the superior mesenteric artery, pulmonary artery, left main renal artery, middle cerebral artery, and septal coronary artery of the rat. In all arteries tested, E 4 had a weaker relaxing potency than E 2 . Pharmacological blockade experiments revealed that E 4 caused relaxation of precontracted rat uterine arteries via both an endothelium-dependent (involving ER) and an ODQ-sensitive mechanism. Furthermore, E 4 inhibited smooth muscle cell Ca 2C entry and contraction, albeit with tenfold lower potency than E 2 .
Estrogens exert their biological effects by binding to specific ERs, primarily ERa and ERb. Previous in vitro binding studies showed that E 4 has moderate affinity for human ERs, with four to five times higher affinity for the ERa compared with the ERb . The same study reported that E 4 has tenfold lower affinity for the ERa compared with the reference compound diethylstilbestrol (DES) and 100-fold lower affinity for the ERb compared with DES . Kitazawa et al. (1997) showed that DES has threefold higher potency than E 2 in relaxing rat femoral arteries. Based on these observations, it was postulated that E 4 would have weaker vasorelaxant potency than E 2 . The current ex vivo arterial reactivity study clearly showed that this is indeed the case for a broad spectrum of rat artery types. E 4 was a much weaker (w14-fold) vasorelaxant than E 2 in PHE-contracted endothelium-intact uterine arteries in the absence of any pharmacological inhibitor. Thus, substitution of two hydrogen atoms for two hydroxyl groups on the carbon 15 and 16 positions of the E 2 molecule appears to result in lower receptor affinity and a reduced functional response. In smaller resistance arteries, e.g. the middle cerebral artery and fourth-order mesenteric artery, E 4 was an even weaker vasorelaxant compared with E 2 . Surprisingly, in larger elastic arteries, such as the thoracic aorta and common carotid artery, the difference in potency between E 4 and E 2 was smaller, mainly because of a reduction in sensitivity to E 2 compared with its sensitivity in smaller arteries. This reduced sensitivity to E 2 in larger arteries is in agreement with findings of others (Lindsey et al. 2011) . Furthermore, the differential sensitivities to E 2 of the mesenteric, renal, and uterine arteries observed in this study are similar to values reported by others (Naderali et al. 1999 , Leung et al. 2005 , Scott et al. 2007 Previous studies have shown that in vivo administration of the nonselective ER antagonist ICI 182 780 into one uterine artery of ovariectomized and E 2 -treated nonpregnant sheep blunted the E 2 effect on uterine blood flow, confirming its ER dependence (Magness et al. 2005) . Here, we show that ICI 182 780 resulted in a significant rightward shift in the CRCs to E 4 and E 2 , suggesting the contribution of ER. However, E 2 -mediated relaxing responses were not inhibited by ICI 182 780 in endothelium-denuded rat uterine arteries (Scott et al. 2007) , most likely because the endothelial layer, which expresses ERs, had been mechanically removed. In vitro studies showed that ERa are localized in caveolae in isolated endothelial cells (Chambliss et al. 2000) , supporting the conclusion that the lack of inhibitory effect of ICI 182 780 in denuded uterine arteries was due to the mechanical removal of the endothelial layer.
We compared relaxing responses to E 4 and E 2 with responses to selective agonists for ERa and ERb in uterine arteries. We showed that the ERa agonist PPT has a more potent relaxing effect on uterine arteries compared with the ERb agonist DPN. This finding is consistent with the study by Montgomory et al. (2003) in which the relative potency of PPT was greater than DPN in relaxing rat mesenteric arteries ex vivo. The order of potency of the estrogenic compounds and ER agonists in relaxing the rat uterine artery is E 2 ZPPTODPNOE 4 .
The current study demonstrated that the relaxing action of E 4 in uterine arteries was L-NAME insensitive, suggesting that endothelium-derived NO plays a marginal role in E 4 -mediated relaxing responses in the rat uterine vasculature. By contrast, relaxing responses to E 2 were partially L-NAME sensitive in rat uterine arteries, similar to earlier observations Figure 3 Relaxing responses to 17b-estradiol (E 2 ; 0 . 1-100 mmol/l; closed symbols) and estetrol (E 4 ; 0 . 1-100 mmol/l; open symbols) in PHE-contracted uterine arteries in the absence of any pharmacological inhibitor (VEH), in the presence of the cyclooxygenase inhibitor INDO (10 mmol/l; A); the NO synthase blocker L-NAME (100 mmol/l; B); the combined presence of L-NAME and INDO (L-NCI; C), the combined presence of L-NAME, INDO, and the selective sGC blocker ODQ (10 mmol/l; L-NCICO; D); the combined presence of L-NAME, INDO, and the selective IK Ca channel blocker TRAM-34 (1 mmol/l) and the selective SK Ca channel blocker UCL 1684 (1 mmol/l; E); and in the presence (CENDO) and absence (KENDO) of endothelium (F). Values are expressed as meanGS.E.M. *P!0 . 05 vs E 4 VEH; **P!0 . 05 vs E 2 VEH. in the in vivo uterine circulation (Van Buren et al. 1992 , Rosenfeld et al. 1996 . Our data do not provide a clear mechanistic explanation for the L-NAME insensitivity of the uterine arterial relaxing responses to E 4 . Neither prostacyclin (PGI 2 ) nor EDHF contributed to the relaxing response to either estrogenic hormone. Surprisingly, pharmacological inhibition of sGC resulted in marked blunting of E 4 -mediated relaxation in uterine arteries, an effort that was not observed in E 2 -treated vessels. Both NO synthase and large-conductance Ca
2C
-activated K C channels (BK Ca ) are involved in acute E 2 -induced vasodilation in oophorectomized nonpregnant ewes (Khan et al. 2000 . NO activates cGMPdependent protein kinase G, which subsequently opens BK Ca on smooth muscle cells, thus decreasing Ca 2C influx via voltage-gated Ca 2C channels, leading to hyperpolarization and relaxation. A more detailed mechanistic study is needed to determine directly whether E 4 can induce the release of cGMP from smooth muscle cells or whether L-NAMEinsensitive intracellular NO stores play a role. Endothelial denudation blunted relaxations to E 4 and E 2 in the uterine artery, probably by disrupting the ER in caveolae on the plasma membrane of endothelial cells.
Both E 4 and E 2 elicited large endothelium-independent relaxation responses, suggesting that estrogenic compounds may interfere with excitation-contraction coupling, thus inhibiting contraction. Excitatory agonists, such as adrenergic agonists and contractile peptides like angiotensin II, can stimulate smooth muscle contraction through three distinct signaling pathways: Ca 2C influx through membrane Ca 2C channels, IP 3 -induced Ca 2C release from the sarcoplasmatic reticulum, and Ca 2C sensitizing mechanisms of the contractile machinery (Somlyo & Somlyo 1994 , Hilgers & Webb 2005 . The contraction-modulating effects of estrogens have been attributed to their Ca 2C antagonistic properties. E 2 can inhibit voltage-dependent calcium inward currents (L-type voltage-operated Ca 2C channels or L-VOCC) located on smooth muscle cells, but not on endothelial cells (Shan et al. 1994 , Zhang et al. 1994 , Nakajima et al. 1995 . This leads to reduced intracellular Ca 2C concentration and subsequent lower Ca 2C -calmodulin-dependent myosin light-chain phosphorylation and contraction. By contrast, E 2 effects have not been ascribed to modulating Ca 2C release from intracellular stores or by IP 3 (Kitazawa et al. 1997) . High K C concentrations (O25 mmol/l) can depolarize the smooth muscle cell membrane and stimulate L-VOCC and Ca 2C influx independent of the endothelium. In Ca 2C -free conditions, no contraction can occur during high K C (60 mmol/l) depolarization. Titration of CaCl 2 into the organ bath results in a Ca 2C -dependent contraction. Using this approach in endothelium-intact uterine arteries, in conditions where NO release and action were blocked, we tested the Ca 2C antagonistic effects of E 4 and found that E 4 and E 2 concentration-dependently blocked L-VOCCdependent contractions in uterine arteries. E 4 was roughly Table 5 Influence of pharmacological inhibitors and endothelial denudation on the vasodilator properties of E 2 compared with E 4 in rat uterine arteries. The sensitivity (pEC 50 ) of E 4 or E 2 is calculated with GraphPad Prism Software as described in the Materials and Methods section and denotes the negative logarithmic concentration of E 4 or E 2 that induces 50% relaxation compared to the maximal relaxation (E max ). See text for inhibitor concentrations used. When more arteries of the same type were isolated from one rat, the values were averaged and regarded as nZ1 per rat. Values are shown as meanGS.E.M.
E 2 E 4
Treatment pEC 50 E max (%) n pEC 50 E max (%) n tenfold less potent than E 2 in inhibiting these contractions. Interestingly, 3 mmol/l E 2 did not block L-VOCC-dependent contractions (Fig. 4A ), but resulted in w50% relaxation of PHE-contracted uterine arteries (Fig. 1A) . The fact that these Ca 2C antagonistic effects of E 4 and E 2 are seen at higher concentrations might suggest that these Ca 2C antagonistic effects are unrelated to their endothelium and ER-dependent estrogenic effects.
In conclusion, we have demonstrated that E 4 is capable of inducing a relaxing response in arteries from a variety of vascular beds. E 4 was several fold less potent than E 2 in relaxing these arteries, but the differential relaxing potency of E 4 vs E 2 decreased in larger arteries, mainly because of reduced potency of E 2 . E 4 caused relaxation of contracted uterine arteries via an endothelium-dependent mechanism involving ERs, as well as smooth muscle-dependent inhibition of Ca 2C entry. The mechanism of the discrepancy between the micromolar range estrogenic effects on ex vivo vasorelaxation and the nanomolar range of circulating estrogen levels in vivo is unclear, but the observation does suggest that the effects of estrogens on ex vivo vasorelaxation are pharmacological in nature. The relatively low vasorelaxing potency of E 4 might be beneficial in clinical use in that E 4 will provide beneficial effects associated with estrogens without altering hemodynamics. Furthermore, previous studies have shown that E 4 (compared with E 2 ) has a low first-pass liver metabolism, no SHBG binding, ER antagonistic effects on breast cancer models, and anti-thrombotic properties, suggesting that E 4 has promise for clinical use as a component hormone in a combined oral contraceptive and as therapy for breast tumors.
